← SynDRA
NAMODENOSON
SynDRA canonical compound SYN0002428 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | ADORA1 | ADORA2A | ADORA2B | ADORA3 |
|---|
| Mechanism of action | adenosine receptor agonist |
|---|
All known targets
- ADORA3
- ADORA1
- ADORA2A
- ADORA2B
Mechanisms of action (all sources)
- ADORA3 AGONIST
- Adenosine A3 receptor agonist
- ADORA1 AGONIST
- ADORA2A AGONIST
- ADORA2B AGONIST
- ADORA3 FULL AGONIST
- adenosine receptor agonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCG2
- PPARG
- PPARD
- HTR2B
- HTR2C
- HTR7
- TARDBP
- SMPD1
- RGS4
- PPARA
- PIN1
- NR3C1
- NR1H3
- NR1H2
- NFE2L2
- HTR6
- ATAD5
- HTR5A
- HTR4
- HTR3A
- HTR2A
- HTR1E
- HTR1D
- HTR1B
- HTR1A
- HDAC6
- GMNN
- TDP1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- AA1R
- AA2AR
- AA2BR
- GALR3
- IL1B
- KSYK
- SYK
- TMIG3
Drug classes
- Purinergic P1 Receptor Agonists
Cross-references
Synonyms
- CF102
- Chloro-ib-meca
- CF-102
- CI-IB-MECA
- CL-IB-MECA
- 2-Cl-IB-Meca
- Cl-IB-MECA
- C-Ibza-MU
- (2S,3S,4R,5R)-5-(2-Chloro-6-((3-iodobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxy-N-methyltetrahydrofuran-2-carboxamide
- UNII-Z07JR07J6C
- 2Cl-IB-MECA
- 1-[2-CHLORO-6-[[(3-IODOPHENYL)METHYL]AMINO]-9H-PURIN-9-YL]-1-DEOXY-N-METHYL-BETA-D-RIBOFURANURONAMIDE
- CHEMBL431733
- Z07JR07J6C
- 2-Chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide
- CF 102
- 2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide
- 2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide
- CF102 compound
- namodenosonum
- RefChem:831715
- A3AdR Agonist CF102
- DTXCID4089995
- Adenosine Receptor A3 Agonist CF102
- Namodenoson [USAN]
- MFCD01861178
- C18H18ClIN6O4
- IPSYPUKKXMNCNQ-PFHKOEEOSA-N
- XS0
- Namodenoson (Standard)
- NAMODENOSON [INN]
- Namodenoson (CF-102)
- Namodenoson (USAN/INN)
- C1-IB-MECA
- Namodenoson (CF-102)?
- GTPL457
- NAMODENOSON [WHO-DD]
- MLS002153535
- orb1300378
Look up NAMODENOSON in the interactive SynDRA portal →